COVID-19
Conditions
Brief summary
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Detailed description
The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).
Interventions
None listed
Sponsors
Methodist Health System
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021. * \>18 years old
Exclusion criteria
* • Outpatient visit * Not admitted to an inpatient or observation status
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of third generation cephalosporin-resistant bacteria (3GCRB) | 5 Months | Incidence of third generation cephalosporin-resistant bacteria (3GCRB) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of ESBLPE | 5 months | Incidence of ESBLPE |
| Incidence of CRB | 5 Months | Incidence of CRB |
| Incidence of other pathogens | August 2021 | * MRSA * VRE * CDI |
| Incidence of nosocomial infections | 5 Months | * Catheter-associated urinary tract infection (CAUTI) * Central line-associated bloodstream infection (CLABSI) * Possible ventilator-associated pneumonia (PVAP) |
| Incidence of clinical outcomes | 5 Months | death, recovery, long-term care facility, etc. |
Countries
United States
Outcome results
None listed